Ding Zigang, Yu Tao, Fang Hongcai, Wang Zhiwei
Department of Hepatobiliary Pancreatic Surgery, The Jiujiang University Affiliated Hospital, No.57, Xunyang East Road, Jiujiang, 332000, Jiangxi Province, China.
Updates Surg. 2025 Aug 12. doi: 10.1007/s13304-025-02276-0.
Liver resection is still the most effective and curative treatment for recurrent liver cancer, laparoscopic repeat liver resection (LRLR) offers an option for recurrent liver cancer due to invasive advantages. However, multicenter, large-sample population-based LRLR has rarely been reported. We aimed to assess the advantages and drawbacks of LRLR compared with laparoscopic and open surgery for recurrent liver cancer by meta-analysis.
Relevant literature was searched using the PubMed, Embase, Cochrane, Ovid Medline, Web of Science databases up to January 16th, 2022. Quality assessment was performed based on a modified version of the Newcastle-Ottawa Scale (NOS). The data were analyzed by Review Manager 5.3. The data were calculated by odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CI) for fixed-effects and random-effects models.
12 retrospective observational studies were suitable for this analysis, involving 1315 patients with 602 undergoing LRLR and 713 undergoing open repeat liver resection (ORLR). Compared with ORLR, LRLR had less intraoperative blood loss (SMD - 0.7, 95% CI - 1.01 to - 0.39; P < 0.0001), shorter hospital stay (SMD - 0.57, 95% CI - 0.88 to - 0.27; P = 0.0002), less overall postoperative complications (OR 0.37; 95% CI 0.2-0.68; P = 0.001), and higher R0 resection rate (OR = 2.51, 95% CI 1.5-4.17, P = 0.0004); However, there were no statistically significant differences between LRLR and ORLR regarding operative time (P = 0.68), transfusion rate (P = 0.08), mortality (P = 0.8), and 3-year overall survival (P = 0.72).
LRLR has an advantage in the hospital stay, blood loss, complications rate and R0 resection. LRLR is a very useful, safe technology and feasible choice in patients with the recurrent liver cancer.
肝切除术仍是复发性肝癌最有效且能治愈的治疗方法,腹腔镜下再次肝切除术(LRLR)因其微创优势为复发性肝癌提供了一种选择。然而,基于多中心、大样本人群的LRLR报道较少。我们旨在通过荟萃分析评估LRLR与腹腔镜手术及开放手术治疗复发性肝癌相比的优缺点。
截至2022年1月16日,使用PubMed、Embase、Cochrane、Ovid Medline、Web of Science数据库检索相关文献。基于纽卡斯尔-渥太华量表(NOS)的修改版进行质量评估。数据采用Review Manager 5.3进行分析。采用固定效应模型和随机效应模型,通过比值比(OR)或均数差(MD)及95%置信区间(CI)计算数据。
12项回顾性观察性研究适合该分析,涉及1315例患者,其中602例行LRLR,713例行开放再次肝切除术(ORLR)。与ORLR相比,LRLR术中出血量更少(标准化均数差 -0.7,95%CI -1.01至 -0.39;P <0.0001),住院时间更短(标准化均数差 -0.57,95%CI -0.88至 -0.27;P =0.0002),术后总体并发症更少(OR 0.37;95%CI 0.2 - 0.68;P =0.001),R0切除率更高(OR =2.51,95%CI 1.5 - 4.17,P =0.0004);然而,LRLR与ORLR在手术时间(P =0.68)、输血率(P =0.08)、死亡率(P =0.8)及3年总生存率(P =0.72)方面无统计学显著差异。
LRLR在住院时间、出血量、并发症发生率及R0切除方面具有优势。LRLR是复发性肝癌患者一种非常有用、安全的技术及可行选择。